SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bharat H. Barai who wrote (99)3/5/1997 7:18:00 AM
From: NVestor   of 834
 
To take this cost analysis one step furter (which I realize may, unfortunately, be irrelevant in view of Bill Tomko's post #97).
Is it possible to monitor any blood loss while using Novastan with a hematocrit test alone - which must be substantially cheaper than a complete blood count.

If so, might the insurers, wanting to keep as much of the health care dollar as possible for their vacations, retirement and whatever, see the relavence of an overall cheaper treatment with more expensive Novastan plus cheap monitoring with hematocrit checks vs. cheap Heparin plus expensive monitoring with CBC tests? This, of course, would assume that TXB would figure a price for Novastan that would in fact result in an overall savings worth looking at.

On a different note: Any feeling on what this stock will do if the overall market has a major setback?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News